000274237 001__ 274237
000274237 005__ 20240229154930.0
000274237 0247_ $$2pmid$$apmid:36906639
000274237 0247_ $$2pmc$$apmc:PMC10007832
000274237 0247_ $$2doi$$aDOI: 10.1186/s40164-023-00387-1 
000274237 0247_ $$2doi$$aDOI: 10.1186/s40164-023-00387-1
000274237 037__ $$aDKFZ-2023-00523
000274237 041__ $$aEnglish
000274237 082__ $$a610
000274237 1001_ $$0P:(DE-He78)a65fa5fbdeff5a1bb6ee7de07b820488$$aSteinfass, Tamara$$b0$$eFirst author$$udkfz
000274237 245__ $$aSecretogranin II influences the assembly and function of MHC class I in melanoma.
000274237 260__ $$aLondon$$bBiomed Central$$c2023
000274237 3367_ $$2DRIVER$$aarticle
000274237 3367_ $$2DataCite$$aOutput Types/Journal article
000274237 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1679472052_6241$$xLetter
000274237 3367_ $$2BibTeX$$aARTICLE
000274237 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274237 3367_ $$00$$2EndNote$$aJournal Article
000274237 500__ $$a#EA:A370#LA:A370#
000274237 520__ $$aMelanoma is the deadliest form of skin cancer showing rising incidence over the past years. New insights into the mechanisms of melanoma progression contributed to the development of novel treatment options, such as immunotherapies. However, acquiring resistance to treatment poses a big problem to therapy success. Therefore, understanding the mechanisms underlying resistance could improve therapy efficacy. Correlating expression levels in tissue samples of primary melanoma and metastases revealed that secretogranin 2 (SCG2) is highly expressed in advanced melanoma patients with poor overall survival (OS) rates. By conducting transcriptional analysis between SCG2-overexpressing (OE) and control melanoma cells, we detected a downregulation of components of the antigen presenting machinery (APM), which is important for the assembly of the MHC class I complex. Flow cytometry analysis revealed a downregulation of surface MHC class I expression on melanoma cells that showed resistance towards the cytotoxic activity of melanoma-specific T cells. IFNγ treatment partially reversed these effects. Based on our findings, we suggest that SCG2 might stimulate mechanisms of immune evasion and therefore be associated with resistance to checkpoint blockade and adoptive immunotherapy.
000274237 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000274237 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000274237 650_7 $$2Other$$aHLA
000274237 650_7 $$2Other$$aMHC class I
000274237 650_7 $$2Other$$aMelanoma
000274237 650_7 $$2Other$$aPrognosis
000274237 650_7 $$2Other$$aSCG2
000274237 7001_ $$0P:(DE-He78)88a268b9173c651561385cddfdf819fa$$aPoelchen, Juliane$$b1$$udkfz
000274237 7001_ $$0P:(DE-He78)f1f0076fc72606659a5df2605acce91b$$aSun, Qian$$b2$$udkfz
000274237 7001_ $$0P:(DE-He78)eb931fe38d70f73c17ed3a90ac3664bb$$aMastrogiulio, Giovanni$$b3$$udkfz
000274237 7001_ $$0P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758$$aNovak, Daniel$$b4$$udkfz
000274237 7001_ $$0P:(DE-He78)61de47f47323d5d0b1700e8213e5179f$$aVierthaler, Marlene$$b5
000274237 7001_ $$0P:(DE-HGF)0$$aPardo, Sandra$$b6
000274237 7001_ $$0P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9$$aFederico, Aniello$$b7$$udkfz
000274237 7001_ $$0P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211$$aHüser, Laura$$b8$$udkfz
000274237 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b9$$udkfz
000274237 7001_ $$0P:(DE-He78)86723b26e79aa190a6c7294651a80986$$aCarretero, Rafael$$b10$$udkfz
000274237 7001_ $$0P:(DE-He78)81ae96953d6149e4307057d71a190019$$aOffringa, Rienk$$b11$$udkfz
000274237 7001_ $$0P:(DE-He78)e6057131c71c90a6fcf61035f12b46c3$$aAltevogt, Peter$$b12$$udkfz
000274237 7001_ $$0P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aUmansky, Viktor$$b13$$udkfz
000274237 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b14$$eLast author$$udkfz
000274237 773__ $$0PERI:(DE-600)2669066-4$$aDOI: 10.1186/s40164-023-00387-1$$gVol. 12, no. 1$$n1$$p29$$tExperimental hematology & oncology$$v12$$x2162-3619$$y2023
000274237 909CO $$ooai:inrepo02.dkfz.de:274237$$pVDB
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a65fa5fbdeff5a1bb6ee7de07b820488$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)88a268b9173c651561385cddfdf819fa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f1f0076fc72606659a5df2605acce91b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eb931fe38d70f73c17ed3a90ac3664bb$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)86723b26e79aa190a6c7294651a80986$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81ae96953d6149e4307057d71a190019$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e6057131c71c90a6fcf61035f12b46c3$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000274237 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000274237 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000274237 9141_ $$y2023
000274237 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000274237 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000274237 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-11
000274237 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-11
000274237 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXP HEMATOL ONCOL : 2022$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:21Z
000274237 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:21Z
000274237 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:21Z
000274237 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-22
000274237 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEXP HEMATOL ONCOL : 2022$$d2023-08-22
000274237 9202_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000274237 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000274237 9201_ $$0I:(DE-He78)D220-20160331$$kD220$$lDKFZ -Bayer Healthcare Joint$$x1
000274237 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000274237 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000274237 9201_ $$0I:(DE-He78)D200-20160331$$kD200$$lMolekulare Grundlagen Gastrointestinaler Tumoren$$x4
000274237 9200_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000274237 980__ $$ajournal
000274237 980__ $$aVDB
000274237 980__ $$aI:(DE-He78)A370-20160331
000274237 980__ $$aI:(DE-He78)D220-20160331
000274237 980__ $$aI:(DE-He78)B062-20160331
000274237 980__ $$aI:(DE-He78)C060-20160331
000274237 980__ $$aI:(DE-He78)D200-20160331
000274237 980__ $$aUNRESTRICTED